Sutro Biopharma, Inc.
STRONASDAQHealthcare● Active
$25.95
+$0.54(+2.13%)
Market Cap$251124793
P/E Ratio—
52W High$43.85
52W Low$6.7
Sutro Biopharma, Inc.（STRO）· 资产负债表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · STRO · 截至 2026-06-10
财务报表
Total Assets · Total Liabilities · Equity
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & ST Investments | $0.14B | $0.32B | $0.38B | $0.33B | $0.20B |
| Net Receivables | $0.00B | $0.01B | $0.04B | $0.01B | $0.01B |
| Inventory | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Current Assets | $0.15B | $0.34B | $0.42B | $0.35B | $0.22B |
| PP&E Net | $0.02B | $0.04B | $0.04B | $0.05B | $0.05B |
| Goodwill | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Intangible Assets | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Assets | $0.17B | $0.39B | $0.47B | $0.41B | $0.34B |
| Liabilities | |||||
| Short-Term Debt | $0.01B | $0.00B | $0.00B | $0.02B | $0.01B |
| Accounts Payable | $0.01B | $0.01B | $0.01B | $0.00B | $0.01B |
| Total Current Liabilities | $0.08B | $0.13B | $0.09B | $0.07B | $0.04B |
| Long-Term Debt | $0.01B | $0.00B | $0.00B | $0.00B | $0.02B |
| Total Liabilities | $0.31B | $0.34B | $0.32B | $0.19B | $0.09B |
| Stockholders Equity | |||||
| Retained Earnings | ($0.98B) | ($0.79B) | ($0.56B) | ($0.45B) | ($0.33B) |
| Total Stockholders Equity | ($0.13B) | $0.04B | $0.15B | $0.22B | $0.25B |
| Total Liab & Equity(computed) | $0.17B | $0.39B | $0.47B | $0.41B | $0.34B |
| Debt Summary | |||||
| Total Debt | $0.02B | $0.02B | $0.03B | $0.06B | $0.06B |
| Net Debt | ($0.04B) | ($0.17B) | ($0.04B) | $0.01B | $0.03B |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解Sutro Biopharma, Inc.
关于Sutro Biopharma, Inc.（STRO）资产负债表
Sutro Biopharma, Inc.总资产$0.17B，现金及短期投资$0.14B，总负债$0.31B，总债务$0.02B，股东权益($0.13B)。
常见问题
STRO · 4 问Sutro Biopharma, Inc.总债务$0.02B，净债务($0.04B)。
STRO total debtnet debtdebt to equity
· Source: FMP /stable/balance-sheet-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10